Clinical trials: Demodicosis
Meibomian Gland Dysfunction, Blepharitis
Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD
The purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop, BID vs TID dosing regimens for the treatment of meibomian gland dysfunction in patients with Demodex lid infestation.
- Conditions
- Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation
- Trial name
- Ersa (NCT05454956)
- Testing
- TP-03, TP-03 Vehicle
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Tarsus Pharmaceuticals, Inc.